Stay updated on ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to include a new study on Metastatic Pancreatic Cancer, identified as ACE-ST-003, and has revised its version number to v2.15.0. The previous study details and inclusion/exclusion criteria have been removed.SummaryDifference16%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check95 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page.